• Business & Finance

    ERYTECH Provides Business and Financial Update for the Third Quarter of 2021

    ERYTECH Provides Business and Financial Update for the Third Quarter of 2021 Conference call and webcast on Tuesday, November 16, 2021at 8:30am EST / 2:30pm CET Progress towards seeking approval of eryaspase for the treatment of ALL patients who experienced hypersensitivity to pegylated asparaginase; Fast Track designation granted; submission of BLA intended around year-end Phase 3 trial in second–line pancreatic cancer did not meet its primary endpoint Process to review strategic options and partnering alternatives launched Cambridge, MA (U.S.) and Lyon (France), November 15, 2021 – ERYTECH Pharma (Nasdaq  

    Comments Off on ERYTECH Provides Business and Financial Update for the Third Quarter of 2021